Trimetazidine-Teva is an antihypoxic drug stimulating metabolism of the myocardium and sensorineural organs in case of ischemia. Trimetazidine is usually prescribed as a long-term treatment of angina pectoris, and in some countries (including France) for tinnitus and dizziness.
It improves left ventricular function in diabetic patients with coronary heart disease. Recently, it has been shown to be effective in patients with heart failure of different etiologies.
Trimetazidine inhibits beta-oxidation of fatty acids by blocking long-chain 3-ketoacyl-CoA thiolase, which enhances glucose oxidation. By preserving energy metabolism in cells exposed to hypoxia or ischaemia, trimetazidine prevents a decrease in intracellular ATP levels, thereby ensuring the proper functioning of ionic pumps and transmembrane sodium-potassium flow whilst maintaining cellular homeostasis.
Trimetazidine stimulates metabolism of cardiomyocytes and brain neuronal cells, thereby stabilizing oxygen consumption and myocardial contractility. In patients with angina pectoris, the drug has a pronounced effect of reducing blood pressure and regulating the heart rate after several weeks of administration.
Formulation and Packaging
1 tablet contains:
active ingredients: trimetazidine dihydrochloride 20 mg and macrogol;
Dosage and Application
To be administered orally. Dosage is 40-60 mg per day divided into 2-3 intakes. The length of treatment course is to be prescribed by a doctor.
Pregnancy, lactation and hypersensitivity to the components of the drug.
Allergic response (including skin allergies), vertigo or headache.